- Home
- DSP vs STTK Comparison
DSP vs STTK Comparison
Compare DSP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- STTK
- Stock Information
- Founded
- DSP 1999
- STTK 2016
- Country
- DSP United States
- STTK United States
- Employees
- DSP N/A
- STTK N/A
- Industry
- DSP EDP Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- STTK Health Care
- Exchange
- DSP Nasdaq
- STTK Nasdaq
- Market Cap
- DSP 167.4M
- STTK 173.6M
- IPO Year
- DSP 2021
- STTK 2020
- Fundamental
- Price
- DSP $10.07
- STTK $3.50
- Analyst Decision
- DSP Strong Buy
- STTK Strong Buy
- Analyst Count
- DSP 5
- STTK 3
- Target Price
- DSP $11.60
- STTK $10.67
- AVG Volume (30 Days)
- DSP 105.1K
- STTK 155.6K
- Earning Date
- DSP 08-12-2024
- STTK 08-01-2024
- Dividend Yield
- DSP N/A
- STTK N/A
- EPS Growth
- DSP N/A
- STTK N/A
- EPS
- DSP N/A
- STTK N/A
- Revenue
- DSP $243,250,000.00
- STTK $4,123,999.00
- Revenue This Year
- DSP $19.71
- STTK $164.45
- Revenue Next Year
- DSP $12.84
- STTK N/A
- P/E Ratio
- DSP N/A
- STTK N/A
- Revenue Growth
- DSP 20.25
- STTK 380.09
- 52 Week Low
- DSP $4.98
- STTK $1.33
- 52 Week High
- DSP $12.36
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- DSP 42.06
- STTK 47.31
- Support Level
- DSP $10.27
- STTK $3.37
- Resistance Level
- DSP $11.41
- STTK $3.69
- Average True Range (ATR)
- DSP 0.42
- STTK 0.23
- MACD
- DSP -0.05
- STTK 0.06
- Stochastic Oscillator
- DSP 8.22
- STTK 51.92
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.